CN101378739B - 药物的硝基氧基衍生物用于治疗肌肉营养不良症的应用 - Google Patents

药物的硝基氧基衍生物用于治疗肌肉营养不良症的应用 Download PDF

Info

Publication number
CN101378739B
CN101378739B CN200780004219.7A CN200780004219A CN101378739B CN 101378739 B CN101378739 B CN 101378739B CN 200780004219 A CN200780004219 A CN 200780004219A CN 101378739 B CN101378739 B CN 101378739B
Authority
CN
China
Prior art keywords
formula
muscular dystrophy
treatment
drug
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200780004219.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN101378739A (zh
Inventor
E·克莱门蒂
G·科素
S·布鲁尼利
E·翁吉尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ireland Nikekesi Science Co
Original Assignee
Nicox SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox SA filed Critical Nicox SA
Publication of CN101378739A publication Critical patent/CN101378739A/zh
Application granted granted Critical
Publication of CN101378739B publication Critical patent/CN101378739B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN200780004219.7A 2006-02-03 2007-01-23 药物的硝基氧基衍生物用于治疗肌肉营养不良症的应用 Expired - Fee Related CN101378739B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76475506P 2006-02-03 2006-02-03
US60/764,755 2006-02-03
PCT/EP2007/050630 WO2007088123A2 (en) 2006-02-03 2007-01-23 Use of nitrooxyderivative of drug for the treatment of muscular dystrophies

Publications (2)

Publication Number Publication Date
CN101378739A CN101378739A (zh) 2009-03-04
CN101378739B true CN101378739B (zh) 2014-06-04

Family

ID=38004694

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780004219.7A Expired - Fee Related CN101378739B (zh) 2006-02-03 2007-01-23 药物的硝基氧基衍生物用于治疗肌肉营养不良症的应用

Country Status (17)

Country Link
US (1) US8575222B2 (enExample)
EP (2) EP1978947B1 (enExample)
JP (1) JP5745210B2 (enExample)
KR (1) KR20080097989A (enExample)
CN (1) CN101378739B (enExample)
AU (1) AU2007211508B2 (enExample)
CA (1) CA2641816C (enExample)
DK (1) DK1978947T3 (enExample)
ES (1) ES2520893T3 (enExample)
IL (1) IL192299A0 (enExample)
NZ (1) NZ569396A (enExample)
PL (1) PL1978947T3 (enExample)
PT (1) PT1978947E (enExample)
RU (2) RU2560144C2 (enExample)
SI (1) SI1978947T1 (enExample)
WO (1) WO2007088123A2 (enExample)
ZA (1) ZA200805716B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2669269B1 (en) 2005-05-27 2019-05-22 The University of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
CN101534843A (zh) 2006-08-01 2009-09-16 普里克萨斯医药股份有限公司 泊洛沙姆用于预防和/或治疗心力衰竭的用途
JP2010523612A (ja) * 2007-04-13 2010-07-15 ニコックス エス エイ アトルバスタチン４−（ニトロオキシ）ブチルエステルの結晶形態
EP2234625B8 (en) 2007-12-17 2013-10-30 The Regents of the University of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
AU2009231258A1 (en) * 2008-04-04 2009-10-08 Biomarin Iga Limited Compounds for treating muscular dystrophy
WO2010108843A1 (en) 2009-03-27 2010-09-30 Nicox S.A. Use of nitrooxyderivative of paracetamol for the treatment of muscular dystrophies
EP2467173B8 (en) 2009-08-21 2019-06-19 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
US9023890B2 (en) 2009-12-02 2015-05-05 The Charlotte-Mecklenburg Hospital Authority Nitrate esters and their use for the treatment of muscle and muscle related diseases
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118819A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
US9452117B2 (en) 2011-06-01 2016-09-27 The Charlotte-Mecklenburg Hospital Authority Nitrate esters and their use for the treatment of muscle and muscle related diseases
US9844599B2 (en) 2013-01-21 2017-12-19 Apparao Satyam Nitric oxide releasing produgs of therapeutic agents
RU2517259C1 (ru) * 2013-03-06 2014-05-27 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук (ГНЦ РФ-ИМБП РАН) Способ профилактики и снижения деструкции белков скелетных мышц при их атрофии, вызванной гипокинезией и/или гравитационной разгрузкой
WO2014169976A1 (en) * 2013-04-18 2014-10-23 Nicox Science Ireland Quinone based nitric oxide donating compounds
US9974767B2 (en) 2014-07-14 2018-05-22 University Of Washington Statins in the treatment of muscular dystrophies and myopathies
KR101661332B1 (ko) 2015-05-28 2016-09-29 (의료)길의료재단 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
US10993993B2 (en) 2015-05-28 2021-05-04 Immunoforge Co., Ltd. Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
AR111295A1 (es) 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
CA3090241C (en) 2018-04-25 2023-03-28 Oncocross Co.,Ltd. Composition for preventing and treating muscular disease
WO2020055186A1 (ko) 2018-09-14 2020-03-19 고려대학교 산학협력단 If1 을 유효성분으로 함유하는 비만 또는 근감소증의 예방 또는 치료용 약학 조성물
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
MX2022003025A (es) 2019-09-19 2022-04-07 Forma Therapeutics Inc Activacion de la piruvato cinasa r.
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
KR102329853B1 (ko) 2021-03-25 2021-11-23 주식회사 엔테로바이옴 아커만시아 뮤시니필라 균주를 포함하는 근위축증 예방 또는 치료용 약학적 조성물
KR102272616B1 (ko) 2021-03-25 2021-07-05 주식회사 엔테로바이옴 피컬리박테리움 프로스니치 균주를 포함하는 근위축증 예방 또는 치료용 약학적 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995030641A1 (en) * 1994-05-10 1995-11-16 Nicox S.A. Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities
WO2000053191A2 (en) * 1999-03-11 2000-09-14 The University Of Manitoba Modulation of skeletal muscle precursor cell activation
EP1473288A1 (en) * 1996-09-04 2004-11-03 Nicox S.A. Nitric ester derivatives of COX-2 inhibitors and their use for treating inflammation and cardiovascular diseases
WO2004105754A1 (en) * 2003-05-27 2004-12-09 Nicox S.A. Nitrooxyderivatives of fluvastatin, pravastatin, cerivastatin, atorvastatin and rosuvastatin as cholesterol-reducing agents with improved anti-inflammatory, antithrombotic and antiplatelet activity
WO2005023305A2 (en) * 2003-09-10 2005-03-17 Inpharmatica Limited Modulating cell activity by using an agent that reduces the level of cholesterol within a cell

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583101A (en) * 1994-07-15 1996-12-10 Harvard College Use of nitrogen oxide species and adducts to inhibit skeletal muscle contraction
FR2794647A1 (fr) * 1999-06-11 2000-12-15 Centre Nat Rech Scient Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules
ITMI991517A1 (it) 1999-07-09 2001-01-09 Nicox Sa Procedimento per ottenere nitrossimetil fenil esterni di derivati dell'acido salicilico
IT1313596B1 (it) * 1999-08-04 2002-09-09 Nicox Sa Processo per la preparazione di nitrossialchil esteri del naproxene
ITMI20011744A1 (it) * 2001-08-09 2003-02-09 Nicox Sa Farmaci per le vasculopatie
ITMI20021392A1 (it) * 2002-06-25 2003-12-29 Nicox Sa Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'
WO2005023189A2 (en) * 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
CA2611140C (en) * 2005-06-09 2013-11-19 University Of Manitoba Compositions and methods for enhancing nitric oxide delivery
EP1983975B1 (en) 2006-02-03 2015-07-29 Giulio Cossu Method of treatment for muscular dystrophy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995030641A1 (en) * 1994-05-10 1995-11-16 Nicox S.A. Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities
EP1473288A1 (en) * 1996-09-04 2004-11-03 Nicox S.A. Nitric ester derivatives of COX-2 inhibitors and their use for treating inflammation and cardiovascular diseases
WO2000053191A2 (en) * 1999-03-11 2000-09-14 The University Of Manitoba Modulation of skeletal muscle precursor cell activation
WO2004105754A1 (en) * 2003-05-27 2004-12-09 Nicox S.A. Nitrooxyderivatives of fluvastatin, pravastatin, cerivastatin, atorvastatin and rosuvastatin as cholesterol-reducing agents with improved anti-inflammatory, antithrombotic and antiplatelet activity
WO2005023305A2 (en) * 2003-09-10 2005-03-17 Inpharmatica Limited Modulating cell activity by using an agent that reduces the level of cholesterol within a cell

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BREDT D S.NO skeletal muscle derived relaxing factor in duchenne muscular dystrophy.《PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 》.1998,第95卷(第25期), *
CHIROLI V ET AL.Nitric oxide-donating non-steroidal anti-inflammatory drugs:the case of nitroderivatives of aspirin.《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY ,EDITIONS SCIENTIFIQUE ELSEVIER,PARIS,FR》.2003,第38卷(第4期),
CHIROLI V ET AL.Nitric oxide-donating non-steroidal anti-inflammatory drugs:the case of nitroderivatives of aspirin.《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,EDITIONS SCIENTIFIQUE ELSEVIER,PARIS,FR》.2003,第38卷(第4期), *
ENGVALL EVA ET AL.The new frontier in muscular dystrophy research:booster genes.《THE FASEB JOURNAL:OFFICIAL PUBLICATION FOR EXPERIMENTAL BIOLOGY 》.2003,第17卷(第12期), *
ONGINI ENNIO ET AL.Nitric oxide (NO)-releasing statin derivatives,a class of drugs showing enhanced antiproliferative and antiinflammatory properties.《PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA》.2004,第101卷(第22期), *
ONGINIENNIOETAL.Nitricoxide(NO)-releasingstatinderivatives a class of drugs showing enhanced antiproliferative and antiinflammatory properties.《PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA》.2004
WEHLING M ET AL.A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice.《THE JOURNAL OF CELL BIOLOGY 》.2001,第155卷(第1期), *

Also Published As

Publication number Publication date
NZ569396A (en) 2011-06-30
EP2786749A1 (en) 2014-10-08
ES2520893T3 (es) 2014-11-12
DK1978947T3 (da) 2014-11-03
KR20080097989A (ko) 2008-11-06
AU2007211508B2 (en) 2012-08-23
WO2007088123A2 (en) 2007-08-09
WO2007088123A3 (en) 2007-09-20
PT1978947E (pt) 2014-11-03
RU2011118522A (ru) 2012-11-20
JP5745210B2 (ja) 2015-07-08
CA2641816C (en) 2016-01-05
HK1129592A1 (en) 2009-12-04
CA2641816A1 (en) 2007-08-09
IL192299A0 (en) 2009-08-03
AU2007211508A1 (en) 2007-08-09
US20090093510A1 (en) 2009-04-09
SI1978947T1 (sl) 2014-12-31
RU2008135153A (ru) 2010-03-10
US8575222B2 (en) 2013-11-05
EP1978947B1 (en) 2014-08-13
PL1978947T3 (pl) 2015-03-31
ZA200805716B (en) 2009-11-25
RU2429828C2 (ru) 2011-09-27
EP1978947A2 (en) 2008-10-15
CN101378739A (zh) 2009-03-04
JP2009525302A (ja) 2009-07-09
RU2560144C2 (ru) 2015-08-20

Similar Documents

Publication Publication Date Title
CN101378739A (zh) 药物的硝基氧基衍生物用于治疗肌肉营养不良症的应用
US20220354857A1 (en) Aldehyde conjugates and uses thereof
JP2022504601A (ja) Ｍｓｔ１キナーゼ阻害剤及びその使用
JP2025114555A (ja) 皮下注射のためのケタミン製剤
RU2204388C2 (ru) ИБУПРОФЕНОВЫЙ ТИОЭФИР В КАЧЕСТВЕ ИНГИБИТОРА, ЗАВИСЯЩЕГО ОТ Nf-kB ОБРАЗОВАНИЯ МЕДИАТОРОВ ВОСПАЛЕНИЯ И БОЛИ
JP2005526768A (ja) 炎症関連遺伝子を調節するデキサナビノール及びデキサナビノール類似体
US8198317B2 (en) Methylenedioxy phenolic compounds and their use to treat disease
PT2120919E (pt) Nova combinação para utilização no tratamento de perturbações inflamatórias
ES2395120T3 (es) Combinación de pemirolast y ramotrobán para su uso en el tratamiento de transtornos inflamatorios
US8802726B2 (en) Use of nitrooxyderivative of drug for the treatment of muscular dystrophies
US20170304336A1 (en) Combination
HK1129592B (en) Use of nitrooxyderivative of drug for the treatment of muscular dystrophies
CN117396505A (zh) 治疗炎症的方法
JP2020532591A (ja) 肝臓の線維症を治療、予防、又は改善するためのγ−ケトアルデヒド捕捉剤の組成物とその使用の方法
Cores Esperón et al. NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases
Dinar A review on the emerging role of SIRT6 in cardiovascular diseases
WO2010108843A1 (en) Use of nitrooxyderivative of paracetamol for the treatment of muscular dystrophies
BR112018076765B1 (pt) Composição para inibir a conversão de colina em trimetilamina (tma)
Kaur Saini et al. Evaluación de la respuesta quimiopreventiva de dos inhibidores de la ciclooxigenasa 2, etoricoxib y diclofenaco en el cáncer de colon murino empleando las técnicas espectroscópicas FTIR Y NMR
WO2014162106A1 (fr) Nouveaux derives de chalcone presentant une activite anti-allergique

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1129592

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: NICOX SCIENCE IRELAND LIMITED

Free format text: FORMER OWNER: NICOX S.A.

Effective date: 20141021

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20141021

Address after: Dublin, Ireland

Patentee after: Ireland Nikekesi science company

Address before: French Sophia Antti Boris

Patentee before: Nicox S. A.

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1129592

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140604

Termination date: 20160123

EXPY Termination of patent right or utility model